NCT06933056

Comparison of Antiplatelet Effects of Sotagliflozin to FDA-approved Antiplatelet Drugs

Comparison of Antiplatelet Effects of Sotagliflozin to FDA-approved Antiplatelet Drugs: an Interventional Study

• Status: Recruiting
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 20 (estimated)
• Sponsor: University of Michigan · Academic / Other
• Sex: All
• Age: 18 Years – 79 Years
• Healthy volunteers: Accepted

Summary

This study will identify the potential benefits of regulating platelet activation with sotagliflozin compared to other FDA-approved drugs known to limit platelet activation.

Conditions

• Platelet Function and Reactivity Tests

Interventions

Type	Name	Description
DRUG	Sotagliflozin (SOTA) followed by 3 drugs in a random order	400 mg/day SOTA Each drug will be given daily for 2 weeks.
DRUG	Aspirin followed by 3 drugs in a random order	81 mg/day Aspirin Each drug will be given daily for 2 weeks.
DRUG	Clopidogrel followed by 3 drugs in a random order	75 mg/day clopidogrel Each drug will be given daily for 2 weeks.
DRUG	Eliquis followed by 3 drugs in a random order	5 mg orally twice daily Eliquis Each drug will be given daily for 2 weeks.

Timeline

• Start date: 2025-09-02
• Primary completion: 2026-09-01
• Completion: 2026-09-01
• First posted: 2025-04-18
• Last updated: 2025-09-15

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study